MICROBOT MEDICAL INC

MBOT is the ticker symbol for Microbot Medical Inc., a company focused on developing robotic medical technologies. Its stock is listed on the Nasdaq Capital Market, allowing investors to buy and sell shares through brokerage accounts. MBOT does not currently pay dividends, and its share price can be volatile because the company is in a developmental stage. For the latest price and market data, refer to the MBOT quote on this page.

Recent performance for MBOT depends on its closing price and trading volume on the Nasdaq. Since MBOT is a small-cap, development-stage medical device company, its stock often moves on news about clinical trials, regulatory filings, or financing activities rather than steady operational results. Check the interactive chart and performance table on this page for the latest weekly, monthly, and year-to-date returns.

Because MBOT may not have consistent earnings or revenue, traditional valuation metrics like the P/E ratio may not be meaningful. Investors often look at price-to-book, price-to-sales, and cash balances instead. Comparing MBOT's market capitalization and enterprise value to peers in the medical device sector can provide context. The latest valuation metrics for MBOT are available in the key statistics section on this page.

MBOT may be available for pre-market and after-hours trading through some brokers, but extended-hours sessions typically have lower liquidity, wider spreads, and higher volatility than regular Nasdaq trading hours. Not all brokers support extended-hours trading for every stock, and orders may not execute if there is insufficient volume. Confirm availability and any associated fees with your brokerage before placing an extended-hours order for MBOT.

For a development-stage company like MBOT, useful metrics include cash and cash equivalents, total debt, operating expenses, and net loss, since these indicate how long the company can fund its operations. Revenue growth and gross margin matter if MBOT has commercial products. Investors may also track research and development spending and share count changes. Review MBOT's latest quarterly and annual financial statements on this page for specific figures.

MBOT faces risks common to small-cap medical device companies, including clinical trial uncertainty, regulatory approval delays, and the need to raise additional capital, which can dilute existing shareholders. Its stock may be thinly traded, making the price sensitive to large orders. Competition, manufacturing challenges, and reliance on key personnel are additional factors. The risk factors section of MBOT's annual report provides a detailed discussion of these and other risks.